Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 12/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 10/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delafloxacin SCHEMBL294694 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL29379152 | 1.00 | CYP3A4 (0.86) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL29631821 | 0.99 | CYP3A4 (0.85) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL441203 | 0.99 | CYP3A4 (0.85) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| Delafloxacin SCHEMBL7248671 | 0.96 | CYP3A4 (0.82) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30626293 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL29080648 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL29080643 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30626258 | 0.93 | CYP3A4 (0.78) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL30593852 | 0.93 | CYP3A4 (0.75) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 730 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR BIOME APS (DK) | 2026-04-30 | — | — | US | claimed |
| EP-4709749-A1 | THERAPEUTIC AGENTS AND COMPOSITIONS AND RELATED METHODS | Koru Biotech Solutions Limited (NZ) | 2026-03-18 | — | — | EP | claimed |
| EP-2969004-B1 | DELAFLOXACIN FOR USE IN TREATING INFECTIONS IN OBESE PATIENTS | MELINTA SUBSIDIARY CORP (US) | 2026-02-25 | — | — | EP | claimed |
| US-12558349-B2 | Methods of treating infections in overweight and obese patients using antibiotics | MELINTA SUBSIDIARY CORP. (US) | 2026-02-24 | — | — | US | claimed |
| EP-3919057-B1 | ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS | MELINTA SUBSIDIARY CORP (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | claimed |
| EP-4658292-A1 | PRODUCTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF PSEUDOMONAS INFECTIONS | The Administrators of The Tulane Educational Fund (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4603146-A2 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | Helperby Therapeutics Limited (GB) | 2025-08-20 | — | — | EP | claimed |
| EP-4022079-A1 | SYSTEMS AND METHODS FOR PERFORMING ANTIMICROBIAL SUSCEPTIBILITY TESTING | Selux Diagnostics, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022140631-A1 | EXO VII INHIBITOR AND QUINOLONE ANTIBIOTIC COMBINATION USEFUL FOR TREATING BACTERIAL INFECTIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-30 | — | — | WO | claimed |
| EP-2999711-B1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | claimed |
| CN-114668769-A | Antibacterial product and preparation method and application thereof | 心远(广州)药物研究有限公司 | 2022-06-28 | — | — | CN | claimed |
| US-20220170104-A1 | BACTERIAL ETIOLOGY OF COLORECTAL CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2022-06-02 | — | — | US | claimed |
| CN-114366713-A | Delafloxacin injection and preparation method thereof | 鲁南制药集团股份有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-111135182-B | Antibacterial product and preparation method and application thereof | 心远(广州)药物研究有限公司 | 2022-04-15 | — | — | CN | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| CN-114031607-A | Refining method of delafloxacin and intermediate thereof | 海南普利制药股份有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-3943112-A2 | REPURPOSED ANTIBIOTICS FOR NON-NUCLEAR GENOTOXIC CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER CONTAINING THE SAME | Korea University Research and Business Foundation (KR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115234-A1 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | AADAT, NAT1, IDO1 | CYP3A4 2727/4885CYP2C9 2357/4885ALDH1A1 123/4885 |
| US-12558349-B2 | Methods of treating infections in overweight and obese patients using antibiotics | CUTA, PADI4, FABP4 | CYP3A4 341/4885CYP2C9 281/4885ALDH1A1 2750/4885 |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | PTMS, CYP24A1, PHPT1 | CYP3A4 501/4885CYP2C9 1353/4885ALDH1A1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.